MétaCan
Menu
Back to cohort
Record W2594127289 · doi:10.1111/jdv.14109

What lies beneath actinic keratosis? Looking beyond visible lesions to optimize patient outcomes

2017· editorial· en· W2594127289 on OpenAlexaboutno aff
John T. Lear

Bibliographic record

VenueJournal of the European Academy of Dermatology and Venereology · 2017
Typeeditorial
Languageen
FieldMedicine
TopicNonmelanoma Skin Cancer Studies
Canadian institutionsnot available
Fundersnot available
KeywordsActinic keratosisMedicineDermatologyField cancerizationKeratosisVenereologyAtypiaActinic keratosesPathologyBasal cell

Abstract

fetched live from OpenAlex

This supplement presents a summary of the key topics discussed at two satellite symposia presented at the 23rd World Congress of Dermatology Meeting which took place in June 2015 in Vancouver, Canada, and at the 24th European Association of Dermatology and Venereology in Copenhagen, Denmark, held during October 2015. These meetings provided important opportunities to explore the need for treating the field in actinic keratosis (AK) and the role of AK treatment modalities and management styles in meeting patient needs. Intraepithelial UV-induced damage, known as field cancerization or field disease, which can eventually transform into AK, is the precursor of most cutaneous invasive squamous cell carcinomas (iSCCs).1 Traditionally, AK is classified using a three-tiered system depending on whether the focal atypia of basal keratinocytes involves the lower third of the epidermis (AK I), the lower two-thirds (AK II) or the full epidermal thickness (AK III). Until recently, it was widely accepted that progression form AK to iSCC could only occur after an almost complete transformation of the epidermis, following a ‘classical pathway’ of stepwise progression. Thus, AK I lesions were typically considered ‘low risk’.2 However, recent evidence suggests that AK I lesions are the most common precursors of iSCC (emerging through a ‘differentiated pathway’) suggesting that ‘low risk’ AK lesions cannot be easily identified.3 Dr Maria Fernandez Figueras discusses the implications of this finding in clinical practice. Mutations in the p53 tumor suppression gene caused by sunlight have been shown to occur not only in visible AK lesions but also in other skin that has been exposed to sunlight (known as the field).4, 5 Therefore, in the context of AK, field disease is an area of subclinical genetic changes in the periphery of visible AKs;6 indeed, new imaging techniques have confirmed that the disease often affects the entire field that has been exposed to sun.7, 8 Professor Eggert Stockfleth stresses the importance of treating the whole field with the goal of eliminating not just the visible lesions, but also the subclinical AKs, thereby minimizing the risk of recurrence, and potentially preventing progression to iSCC.9, 10 Dr Gary Goldenberg continues with this theme, focussing on the efficacy, safety and tolerability of current treatment options available for AK, paying particular attention to patient-applied field therapies and their suitability depending on specific disease characteristics and patient needs. Finally, Professor Rino Cerio discusses barriers to the effective treatment of AK, providing strategies to overcome these barriers, with a focus on patient education (including sun protection, using treatments correctly and self-checks) and timely follow-ups, delivered within the framework of patient-centered care. I hope that these discussions will assist you in making the best choices in close partnership with your patients, leading to improved treatment adherence, reduced subclinical damage, improved rates of sustained clearance of AKs and ultimately the potential for reduced risk of progression to iSCC. Dr Lear reports receiving funds from LEO Pharma during the development of the manuscript. This supplement was funded by LEO Pharma. It is a publication based on the content presented at the LEO Pharma supported satellite symposia to WCD (Canada) and JEADV (Denmark) in 2015. The publication presents views of the author(s) and not necessarily LEO Pharma. Lucid Group, funded by LEO Pharma, is gratefully acknowledged for editorial support in the preparation of this publication.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Editorial · Consensus signal: none
Teacher disagreement score0.581
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.000
Science and technology studies0.0000.001
Scholarly communication0.0000.000
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.317
Teacher spread0.298 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreEditorial

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the European Academy of Dermatology and VenereologySame topicNonmelanoma Skin Cancer StudiesFrench-language works237,207